Dissecting individual current components of co-expressed human P2X1 and P2X7 receptors

Current Topics in Medicinal Chemistry

Volumn 4, Issue 16, 2004, Pages 1719-1730

  Seyffert, Christian ^a   Schmalzing, Günther ^b   Markwardt, Fritz ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Agonist; Antagonist; Kinetics; Oocyte; P2X receptor; Purinergic receptor; Subtype; Whole cell current

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 2',3' O (4 BENZOYL)BENZOYLADENOSINE TRIPHOSPHATE; 2, 3 DIALDEHYDE ADENOSINE TRIPHOSPHATE; 4,4',4'',4''' [CARBONYLBIS[IMINO 5,1,3 BENZENETRIYLBIS(CARBONYLIMINO)]]TETRAKIS BENZENE 1,3 DISULFONIC ACID; 8,8' [CARBONYLBIS(IMINO 4,1 PHENYLENECARBONYLIMINO 4,1 PHENYLENECARBONYLIMINO)] BIS(1,3,5 NAPHTHALENETRISULFONIC ACID); ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE MAGNESIUM; ALPHA,BETA METHYLENEADENOSINE TRIPHOSPHATE; BRILLIANT BLUE; NF 279; NF 449; PURINE P2X1 RECEPTOR; PURINE P2X7 RECEPTOR; PURINE P2X7 RECEPTOR STIMULATING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; RECEPTOR SUBTYPE; SURAMIN; UNCLASSIFIED DRUG;

CELL TYPE; CONCENTRATION RESPONSE; DESENSITIZATION; ELECTROPHYSIOLOGY; EPITHELIUM CELL; HUMAN; LYMPHOCYTE; OOCYTE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; REVIEW; XENOPUS;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADENOSINE TRIPHOSPHATE; ANIMALS; BENZENESULFONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; MAGNESIUM; OOCYTES; PATCH-CLAMP TECHNIQUES; RECEPTORS, PURINERGIC P2; SURAMIN; TIME FACTORS; XENOPUS LAEVIS;

EID: 10644278862     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043387160     Document Type: Review

References (52)

1. North, R. A. Molecular physiology of P2X receptors. Physiol. Rev. 2002, 82, 1013-1067.
2. Ralevic, V. and Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev. 1998, 50, 413-492.
3. 1 and P2X3 receptors form stable trimers: A novel structural motiv of ligand-gated ion channels. EMBO J. 1998, 17, 3016-3028.
4. Kim, M,; Spelta, V.; Sim, J.; North, R. A.; and Surprenant, A. Differential assembly of rat purinergic P2X7 receptor in immune cells of the brain and periphery. J. Biol. Chem. 2001, 276, 23262-23267.
5. Sluyter, R.; Barden, J. A., and Wiley, J. S. Detection of P2X purinergic receptors on human B lymphocytes. Cell Tissue Res. 2001, 304, 231-236.
6. 7 purinoceptors. Biophys. J. 1999, 76, A338.
7. Adrian, K.; Bernhard, M. K.; Breitinger, H. G.; and Ogilvie, A. Expression of purinergic receptors (ionotropic P2X1-7 and metabotropic P2Y1-11) during myeloid differentiation of HL60 cells. Biochim. Biophys. Acta 2000, 1492, 127-138.
8. Ray, F. R.; Huang, W.; Slater, M.; and Barden, J. A. Purinergic receptor distribution in endothelial cells in blood vessels: a basis for selection of coronary artery grafts. Atherosclerosis 2002, 162, 55-61.
9. 3,4,6 are up-regulated during apoptosis in the ageing rat prostate. Histochem. J. 2000, 32, 571-580.
10. 1-7) in uterine epithelial cells during early pregnancy. Histochem. J. 2000, 32, 365-372.
11. Cario-Toumaniantz, C.; Loirand, G.; Ladoux, A.; and Pacaud, P. P2X7 receptor activation-induced contraction and lysis in human saphenous vein smooth muscle. Circ. Res. 1998, 83, 196-203.
12. Torres, G. E.; Egan, T. M.; and Voigt, M. M. Hetero-oligomeric assembly of P2X receptor subunits - Specificities exist with regard to possible partners. J. Biol. Chem. 1999, 274 6653-6659.
13. 7 receptor signalling complex. EMBO J. 2001, 20, 6347-6358.
14. El-Moatassim, C. and Dubyak, G. R. Dissociation of the pore-forming and phospholipase D activities stimulated via P2Z purinergic receptors in BAC1.2F5 macrophages - Product inhibition of phospholipase D enzyme activity. J. Biol. Chem. 1993, 268, 15571-15578.
15. Humphreys, B. D.; Rice, J.; Kertesy, S. B.; and Dubyak, G. R. Stress-activated protein kinase/JNK activation and apoptotic induction by the macrophage P2X7 nucleotide receptor. J. Biol. Chem. 2000, 275, 26792-26798.
16. Verhoef, P. A.; Estacion, M.; Schilling, W.; and Dubyak, G. R. P2X7 receptor-dependent blebbing and the activation of Rho-effector kinases, caspases, and IL-1 beta release. J. Immunol. 2003, 170, 5728-5738.
17. 7 receptor-mediated signalling pathway associated with rapid killing of intracellular mycobacteria within human macrophages. Drug Dev. Res. 2001, 53, 105-116.
18. Parker, K. E. Modulation of ATP-gated non-selective cation channel (P2X1 receptor) activation and desensitization by the actin cytoskeleton. J. Physiol. (Lond. ) 1998, 510, 19-25.
19. 7 receptors. Eur. J. Pharmacol. 2000, 387, 245-252.
20. 7 receptors from human B lymphocytes expressed in Xenapus oocytes. Biochim. Biophys. Acta 2000, 1467, 444-456.
21. 7 receptor does not affect its electrophysiological phenotype. Am. J. Physiol. 2003, 284, C749-C756.
22. 1 receptors. Eur. J. Pharmacol. 2003, 470, 1-7.
23. 7 receptor. J. Physiol. (Lond. ) 2001, 534, 25-35.
24. 1 receptor at nanomolar ATP concentrations. J. Gen. Physiol. 2003, 121, 451-461.
25. 1 receptor. J. Biol. Chem. 2004, 279, 6426-6433.
26. Valera, S.; Hussy, N.; Evans, R. J.; Adami, N.; North, R. A.; Surprenant, A.; and Buell, G. A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP. Nature 1994, 371, 516-519.
27. 1 receptor activation in HL60 cells. Blood 1996, 87, 2659-2664.
28. Lewis, C. J. and Evans, R. J. Lack of run-down of smooth muscle P2X receptor currents recorded with the amphotericin permeabilized patch technique, physiological and pharmacological characterization of the properties of mesenteric artery P2X receptor ion channels. Br. J. Pharmacol. 2000, 131, 1659-1666.
29. Bianchi, B. R.; Lynch, K. J.; Touma, E.; Niforatos, W.; Burgard, E. C.; Alexander, K. M.; Park, H. S.; Yu, H.; Metzger, R.; Kowaluk, E.; Jarvis, M. F.; and van Biesen, T. Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur. J. Pharmacol. 1999, 376, 127-138.
30. Evans, R. J.; Lewis, C.; Buell, G.; Valera, S.; North, R. A., and Surprenant, A. Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors). Mol. Pharmacol. 1995, 48, 178-183.
31. 7). Science 1996, 272 735-738.
32. Jacobson, K. A.; Jarvis, M. F.; and Williams, M, Purine and pyrimidine (P2) receptors as drug targets. J. Med. Chem. 2002, 45, 4057-4093.
33. Gargett, C. E.; Cornish, J. E.; and Wiley, J. S. ATP, a partial agonist for the P2Z receptor of human lymphocytes. Br. J. Pharmacol. 1997, 122, 911-917.
34. Lambrecht, G. Agonists and antagonists acting at P2X receptors: selectivity profiles and functional implications. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 362, 340-350.
35. 2Z-Purinoceptor of human lymphocytes: Actions of nucleotide agonists and irreversible inhibition by oxidized ATP. Br. J. Pharmacol. 1994, 112, 946-950.
36. Lambrecht, G.; Braun, K.; Damer, S.; Ganso, M.; Hildebrandt, C.; Ullmann, H.; Kassack, M. U.; and Nickel, P. Structure-activity relationships of suramin and pyridoxal-5′-phosphate derivatives as P2 receptor antagonists. Curr. Pharm. Design 2002, 8, 2371-2399.
37. Murgia, M.; Hanau, S.; Pizzo, P.; Rippa, M.; and Di Virgilio, F. Oxidized ATP - an irreversible inhibitor of the macrophage purinergic-P2Z receptor. J. Biol. Chem. 1993, 268, 8199-8203.
38. Beigi, R. D.; Kertesy, S. B.; Aquilina, G.; and Dubyak, G. R. Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. Br. J. Pharmacol. 2003, 140, 507-519.
39. 7 antagonist, is toxic to rat cerebellar granule neurones in vitro. Neurosci. Lett. 2001, 311, 77-80.
40. 7 receptor-mediated cellular accumulation of YO-PRO-1. Br. J. Pharmacol. 2000, 130, 513-520.
41. 7 receptor. Br. J. Pharmacol. 1998, 124, 1314-1320.
42. 7 nucleotide receptor: High selectivity for the human versus rat receptor homologues. Mol. Pharmacol. 1998, 54, 22-32.
43. Gargett, C. E. and Wiley, J. S. The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. Br. J. Pharmacol. 1997, 120, 1483-1490.
44. 7 receptor orthologs. J. Pharmacol. Exp. Ther. 2001, 296, 947-957.
45. 7 receptors. Mol. Pharmacol. 2000, 58, 82-88.
46. Dubyak, G. R. and El-Moatassim, C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am. J. Physiol. 1993, 265, 577-606.
47. Di Virgilio, F. The P2Z purinoceptor: An intriguing role in immunity, inflammation and cell death. Immunol. Today 1995, 16, 524-528.
48. 4- receptor of rat mast cells. Biochem. J. 1980, 188, 789-798.
49. Di Virgilio, F.; Chiozzi, P.; Ferrari, D.; Falzoni, S.; Sanz, J. M.; Morelli, A.; Torboli, M.; Bolognesi, G.; and Baricordi, O. R. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 2001, 97, 587-600.
50. 7 receptor of microglial cells: a novel immunomodulatory receptor. Prog. Brain Res. 1999, 120, 355-368.
51. Di Virgilio, F. and Solini, A. P2 receptors: new potential players in atherosclerosis. Br. J. Pharmacol. 2002, 135 831-842.
52. Di Virgilio, F.; Ferrari, D.; Idzko, M.; Panther, E.; Norgauer, J.; La Sala, A.; and Girolomoni, G. Extracellular ATP, P2 receptors, and inflammation. Drug Dev. Res. 2003, 59, 171-174.